Prostate Cancer Trial, Recruiting NCT02724670 Sponsor: University Hospital Tuebingen Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT02724670
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with prostate cancer confirmed by a tissue sample (biopsy)
  • People whose cancer is considered suitable for treatment aimed at curing the disease
  • People who are reasonably active and able to carry out daily activities (rated on a standard health scale from 0 to 2, where 0 means fully active and 2 means able to care for oneself but unable to do physical work)
  • People who have given written agreement to take part in the trial

Who may not be able to join:

  • People for whom curative treatment is not considered medically safe or appropriate
  • People under 18 years of age
  • People who have previously had radiotherapy to the pelvic area, or procedures on the prostate such as TURP (a surgical procedure to remove part of the prostate) or HIFU (a treatment using focused sound waves)
  • People with serious health conditions that would make it unsafe to receive image-guided radiotherapy (a type of precise radiation treatment)
  • People who are unable to have an MRI scan, for example due to certain metal implants or other medical reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Arndt-Christian Müller, Dr., Department of Radiation Oncology, University of Tübingen

Phone: 497071/2986142

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital Tuebingen
Registry
ClinicalTrials.gov
Start date
1 March 2016
Est. completion
1 June 2020

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

G2+gastrointestinal and genitourinary toxicity at 2 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov